KeyBanc notes that Salesforce (CRM) announced that Takeda has selected Salesforce Life Sciences Cloud for Customer Engagement. The company will leverage Salesforce’s platform, including Agentforce and Data Cloud, to deploy personalized AI agents, supporting operations from medical to commercial and patient support functions. The loss of Takeda to Salesforce follows news late last year of a different Top 20 pharma company choosing to develop a customized solution with Salesforce instead of Vault CRM, the firm notes. Despite this, KeyBanc points out Veeva (VEEV) expects to retain the vast majority of its Veeva CRM customers, and for most of the top 20 pharma companies to decide on whether to migrate to Vault CRM in 2025 & 2026.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>

>;elm:context_link;itc:0;sec:content-canvas" href="https://www.tipranks.com/screener/top-insider-trading-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">See Insiders’ Hot Stocks on TipRanks >>

Read More on VEEV:

Disclaimer & DisclosureReport an Issue

• Chase Coleman’s Tiger Global buys Zillow, boosts PDD in Q1

• Definitive Healthcare downgraded to Neutral from Buy at BTIG

• Veeva launches Veeva AI

• Veeva price target lowered to $255 from $290 at Piper Sandler

• Veeva price target lowered to $250 from $260 at KeyBanc